Dana-Farber Cancer Institute | Strategic Alliance Partners

May 21, 2024

Haeseong Park, MD, MPH, discusses findings from a phase 1 study of epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

May 20, 2024

Rebecca Porter, MD, PhD, discusses mirvetuximab soravtansine plus pembrolizumab in serous endometrial cancer and future directions for ADCs in the space.

May 13, 2024

Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.

May 13, 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

May 13, 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.

May 10, 2024

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.

May 10, 2024

Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer

May 06, 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

May 06, 2024

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

May 02, 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

May 02, 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

April 29, 2024

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

April 25, 2024

A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.

April 25, 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

April 19, 2024

In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.

April 18, 2024

Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.

April 17, 2024

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

April 15, 2024

The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.

April 11, 2024

Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.

April 11, 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.